All In Biotech

Drug Trial Radar · NCT02612129

Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

50

Actual

Start

Jun 14, 2016

Primary completion

Jun 25, 2018

Study completion Oct 31, 2024

Sponsor

Lead sponsor
ZevraDenmarkIndustry
Sponsor type
Industry
First posted
Nov 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, randomized, double-blind, placebo controlled therapeutic study in participants with confirmed diagnosis of Niemann-Pick disease type C (NPC). The purpose of this study is to assess the efficacy and safety of arimoclomol (compared to placebo) when it is administered as an add-on therapy to the participant's current prescribed best routine clinical care; participant's routine clinical care may, or may not, include miglustat. The CT-ORZY-NPC-002 study has been expanded to include an open label paediatric sub-study including participants aged 6 to \<24 months at study enrolment.

Conditions

  • Niemann-Pick Disease, Type C

Interventions

  • arimoclomolDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Niemann-Pick Disease Type C (NPC) Disease Severity Assessed Based on the 5-domain NPCCSS Total ScoresTime frame: Baseline to Month 12

Locations

14 sites in 9 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Mayo Clinic Children's Center

    Rochester, Minnesota

  • University Hospital Copenhagen (Rigshospitalet)

    Copenhagen, Denmark

  • CHU de Montpellier

    Montpellier, France

  • Hôpital Trousseau

    Paris, France

  • Villa Metabolica, Universitätsmedizin Mainz

    Mainz, Germany

  • Dr. von Haunersches Kinderspital der Universität München

    Munich, Germany

  • Ospedale Pediatrico Bambino Gesù

    Rome, Italy

  • Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udin

    Udine, Italy

  • The Children´s Memorial Istitute Warsaw

    Warsaw, Poland

  • Hospital Vall D'Hebron

    Barcelona, Spain

  • INSELSPITAL University Hospital Bern

    Bern, Switzerland

  • Birmingham Children's Hospital

    Birmingham, United Kingdom

  • Great Ormond Street Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.